Myelodysplastic syndrome 內容預覽:
(點擊下圖可對專家課件進行全文預覽)
Myelodysplastic syndrome 內容簡介:
Myelodysplasticsyndromeoverview
RazelleKurzrock
SeminarsinHaematology,Vol39,No3,Suppl2(July)2002,pp18-25
Myelodysplasticsyndrome(MDS)
Itisatermforaheterogeneouscollectionofhaemopoieticstemcelldisordersaffectingolder**s.
Thereisunderlyingineffectivenessofhaemopoiesisthatresultsindysplasiaofbonemarrowprecursorsandpe**heralcytopenias.
ModerateanaemiaisthemostcommonclinicalprobleminMDSpatients,butcompletemyeloidbonemarrowfailurealsooccursleadingtodeathfrombleedingorinfection.
ApproximatelyhalfofthepatientstransformtoAML.
Prognosisdependsontheindividual’sriskfactors,withmediansurvivalrangingfrom5.7yearsinlower-riskgroupto1.2yearsorlessinthosewithhigher-riskMDS.
MDSisextremelydifficulttotreat.Mostcasesareresistanttocurrenttherapies,andthemostpotentanti-MDStreatments(transplantationanddoseintensivechemotherapy)areoftentootoxicforthemajorityofpatients.
MDSbackground
Pathobiology
ThecardinalfeaturesofMDSare
Increasedmarrowproliferation
Failureofstemcellstodifferentiate
Andincreasedmarrowapoptosis.
Thediseaseisofclonalorigin
Chromosomalabnormalitiesaredetectablein30-70%ofpatients.Theno.ofchromosomalabn.maycorrelatewiththeriskofprogressiontoAML.
FABclassification
In1982TheFABgroupclassifiedMDSaccordingtoMorphologyandthe%ofmyeloblastsintheBMandPB.
Theseincluded
Refractoryanaemia(RA)
Refractoryanaemiawithringedsideroblasts(RARS)
Refractoryanaemiawithexcessblastinmarrow(RAEB)
CMML
Refractoryanaemiawithexcessblastintransformation
(RAEB-t)
WHOclassification
TheWHOproposedchangesincludingreclassificationofRAEB-ttoAMLandaddingasubgroupcalledrefractorycytopeniaswithdysplasia(RCD)
InternationalPrognosticScoringSystem(IPSS)
ThemostpracticalandvalidatedMDSclassificationsystemcurrentlyavailabletocliniciansistheIPSSwhichpredictsbothsurvivalandriskoftransformationtoAMLbasedon:
Marrowblast%
Cytogenetics
Andnumberofcytopenias.
Myelodysplastic syndrome ***下載